See more : Adstar Inc (ADST) Income Statement Analysis – Financial Results
Complete financial analysis of MeiraGTx Holdings plc (MGTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MeiraGTx Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SSAB AB (publ) (SSABAH.HE) Income Statement Analysis – Financial Results
- PolyMet Mining Corp. (POM.TO) Income Statement Analysis – Financial Results
- BRAbank ASA (BRA.OL) Income Statement Analysis – Financial Results
- Cisco Systems Inc (CSCO.NE) Income Statement Analysis – Financial Results
- Optiva Inc. (RKNEF) Income Statement Analysis – Financial Results
MeiraGTx Holdings plc (MGTX)
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.02M | 15.92M | 37.70M | 15.56M | 13.29M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 8.72M | 7.87M | 0.00 | 0.00 | 2.05M | 679.18K | 243.08K |
| Gross Profit | 14.02M | 7.20M | 29.83M | 15.56M | 13.29M | -2.05M | -679.18K | -243.08K |
| Gross Profit Ratio | 100.00% | 45.21% | 79.12% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 103.79M | 85.73M | 67.13M | 33.91M | 24.88M | 33.62M | 22.36M | 14.04M |
| General & Administrative | 47.29M | 46.55M | 43.77M | 44.21M | 46.68M | 44.48M | 9.33M | 6.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.29M | 46.55M | 43.77M | 44.21M | 46.68M | 44.48M | 9.33M | 6.03M |
| Other Expenses | 0.00 | 361.00K | -434.00K | 0.00 | 0.00 | 83.08K | -553.50K | 0.00 |
| Operating Expenses | 151.08M | 132.28M | 110.89M | 78.12M | 71.56M | 78.10M | 31.68M | 20.06M |
| Cost & Expenses | 151.08M | 132.28M | 110.89M | 78.12M | 71.56M | 78.10M | 31.68M | 20.06M |
| Interest Income | 2.27M | 777.00K | 212.00K | 1.28M | 370.60K | 53.41K | 26.07K | 32.07K |
| Interest Expense | 13.25M | 4.95M | 288.00K | 139.20K | 48.61K | 33.43K | 42.86K | 25.44K |
| Depreciation & Amortization | 13.73M | 8.72M | 7.87M | 4.17M | 3.35M | 2.05M | 679.18K | 243.08K |
| EBITDA | -57.05M | -115.95M | -71.40M | -53.68M | -51.35M | -78.10M | -31.01M | -19.82M |
| EBITDA Ratio | -407.02% | -725.99% | -193.58% | -393.75% | -435.58% | 0.00% | 0.00% | 0.00% |
| Operating Income | -137.06M | -116.36M | -73.19M | -62.55M | -58.27M | -78.10M | -31.68M | -20.06M |
| Operating Income Ratio | -977.82% | -730.87% | -194.14% | -401.94% | -438.37% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 53.03M | -13.26M | -6.37M | 4.56M | 3.52M | -5.24M | 640.19K | 272.17K |
| Income Before Tax | -84.03M | -129.62M | -79.56M | -57.99M | -54.75M | -83.34M | -31.04M | -19.79M |
| Income Before Tax Ratio | -599.46% | -814.16% | -211.03% | -372.63% | -411.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.26M | -7.59M | -4.03M | -2.19M | -474.39K | -510.64K | -280.44K |
| Net Income | -84.03M | -142.88M | -71.98M | -53.96M | -52.56M | -82.87M | -31.04M | -19.49M |
| Net Income Ratio | -599.46% | -897.46% | -190.91% | -346.72% | -395.40% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -3.16 | -1.63 | -1.43 | -1.58 | -4.37 | -3.62 | -1.01 |
| EPS Diluted | -1.49 | -3.16 | -1.63 | -1.43 | -1.58 | -4.37 | -3.62 | -1.01 |
| Weighted Avg Shares Out | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M | 19.24M |
| Weighted Avg Shares Out (Dil) | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M | 19.24M |
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapy RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T...
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
LONDON and NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that after a successful inspection by the Irish Health Products Regulatory Authority (HPRA), it has...
MeiraGTx Holdings PLC (MGTX) Soars 8.2%: Is Further Upside Left in the Stock?
MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023
LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company's AAV-hAQP1 clinical...
Does MeiraGTx Holdings PLC (MGTX) Have the Potential to Rally 320.9% as Wall Street Analysts Expect?
The consensus price target hints at a 320.9% upside potential for MeiraGTx Holdings PLC (MGTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
LONDON and NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present clinical data from the Company's AAV-hAQP1 Phase 1 AQUAx...
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -31.03% and 14.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports